Studies on treatment in lung cancer part 1 studies on chemo therapy in advanced lung cancer combination chemo therapy with 5 fluoro uracil vincristine bleomycin cyclo phosphamide and mitomycin c

Fujii, M.

Okayama Igakkai Zasshi 88(11-12): 1031-1038


ISSN/ISBN: 0030-1558
Accession: 006523314

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

A regimen consisting of 5-fluorouracil, vincristine, bleomycin, cyclophosphamide and mitomycin C (FOBEM) was used for the treatment of advanced lung cancer patients. 5-Fluorouracil (250 mg) was administered every other day. Vincristine (1 mg), bleomycin (15 mg), cyclophosphamide (400 mg) and mitomycin C (4 mg) were each administered once a wk for 6 consecutive weeks. Fourteen (28.6%) of 49 evaluated patients had significant tumor regression; 2 of these patients had small cell carcinoma which showed complete regression. Histological classification indicated 17.6% of adenocarcinoma, 35.3% of squamous cell carcinoma and 57.0% of anaplastic carcinoma; 12.5% of patients were diagnosed cytologically or clinically. Patients responding to FOBEM survived about 2 times longer after the initiation of chemotherapy than non-responders; the survival was slightly longer in patients treated with FOBEM than in those administered 1 or 2 of these drugs. In aged patients, pulmonary toxicity of bleomycin was the major dose limiting factor rather than the mild myelosuppressive toxicity and the cumulative pulmonary toxicity necessitated the reduction of this drug. This FOBEM regimen warrants further investigation in the management of small cell and squamous cell carcinoma of the lung.